Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapeutics targeting genetically defined cancers. The company operates within the biotechnology and pharmaceutical research and development industries, with a strategy centered on advancing precision medicines for patients with high unmet medical needs. Its portfolio primarily targets solid tumors and hematologic malignancies through differentiated mechanisms of action.
The company’s primary value drivers are its clinical and preclinical drug candidates, most notably Safusidenib (NUV-655), a selective brain-penetrant IDH1 inhibitor, and Taletrectinib, a ROS1/NTRK inhibitor. Nuvation Bio positions itself as an oncology-focused platform company combining internal discovery with in-licensed assets to build a diversified pipeline. Founded in 2018, the company went public in 2021 through a merger with a special purpose acquisition company (SPAC), enabling expanded capital access to advance its clinical programs.
Business Operations
Nuvation Bio’s operations are organized around drug discovery, clinical development, and regulatory advancement of oncology candidates. The company does not generate commercial product revenue and instead relies on equity financing and cash reserves to fund operations. Its business model is focused on progressing assets through clinical milestones with the intent to seek regulatory approval or strategic partnerships.
The company conducts clinical trials primarily in the United States with additional international trial sites, leveraging third-party contract research organizations rather than owning manufacturing facilities. Key assets are internally developed or licensed, and intellectual property rights are maintained through patents and exclusive agreements. Nuvation Bio operates through wholly owned subsidiaries, including Nuvation Bio Oncology, Inc., which holds rights to several pipeline programs.
Strategic Position & Investments
Nuvation Bio’s strategy emphasizes the development of targeted therapies with improved selectivity and central nervous system penetration, particularly in oncology indications with limited treatment options. Growth initiatives are focused on advancing lead candidates into later-stage clinical trials while maintaining optionality for out-licensing or co-development arrangements.
Major investments include the in-licensing of Safusidenib (NUV-655) and the continued development of Taletrectinib, which was acquired through the acquisition of AnHeart Therapeutics. The company also maintains an early-stage pipeline of oncology programs addressing DNA damage response and epigenetic targets. Emerging technologies within its portfolio include next-generation kinase inhibitors designed to overcome resistance mechanisms.
Geographic Footprint
Nuvation Bio is headquartered in New York, United States, and maintains its principal executive offices there. The company’s operational footprint is primarily concentrated in North America, with clinical trial activities extending into Europe and Asia through global research partnerships and trial sites.
While the company does not have large-scale international manufacturing or commercial operations, its global presence is reflected in multinational clinical studies and regulatory planning for potential future market entry beyond the United States.
Leadership & Governance
Nuvation Bio was founded by David Hung, whose leadership philosophy emphasizes scientific rigor, capital discipline, and long-term value creation through focused oncology innovation. The company is governed by a board and executive team with experience across biotechnology, clinical development, and capital markets.
Key executives include:
- David Hung – Founder, President, and Chief Executive Officer
- Michael Lonergan – Chief Financial Officer
- Andrew Burke – Chief Operating Officer
- Martina M. Fluck – Chief Medical Officer
- David M. Barrett – Chief Business Officer
The leadership team’s strategic vision centers on advancing a differentiated oncology pipeline while maintaining financial flexibility and adherence to regulatory and governance standards.